Arbutus to participate in three upcoming investor conferences

Warminster, pa., feb. 06, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the arbutus management team will participate in and host one-on-one meetings at the following three upcoming investor conferences:
ABUS Ratings Summary
ABUS Quant Ranking